Drug Free Sport International (DFSI) is a global leader in anti-doping and health education for sports, striving to ensure fair and safe competition for athletes worldwide. The 2018 merger with International Doping Tests & Management (IDTM) in Stockholm, Sweden, solidified DFSI's position as the largest third-party sports anti-doping administrator globally, offering specimen collection in over 100 countries. DFSI serves prominent sports organizations such as MLB, NFL, NBA, NASCAR, PGA Tour, LPGA, International Tennis Federation, IAAF, FINA, NCAA, and over 300 colleges and amateur athletics organizations. Moreover, with over three decades of experience, DFSI Research & Healthcare Services utilizes its extensive network to advance diagnostic and pharmaceutical development. The company's services include decentralized clinical trials, at-home and event-based visits, targeted follow-up visits for lost participants, and global sample collection tailored to critical patient populations. Operating at the apex of human performance, DFSI ensures compliance with the strictest international standards and quality assurance, delivering exceptional service to clients, researchers, and patients. DFSI's dedication to integrity in sports and its expansion into healthcare services and research position it as a significant player in the Education, Health Care, Health, and Wellness, and Sports industries. Although specific investment details are not available, DFSI's collaborative efforts with investors present potential opportunities for growth and innovation in the sports and healthcare sectors.
There is no investment information
No recent news or press coverage available for Drug Free Sport International.